Chordoma Foundation Labs

Patient driven research laboratory 100% dedicated to accelerating cures for chordoma. A program of @ChordomaFDN.

[Hannah Abrams, MD @HannahRAbrams]

#ASCO26 Targeting EGFR in #chordoma:

Abstract 11527, @APConley77 #sarcoma
- IIT of cetuximab in met/unresect chordoma
- n = 25 evaluable
- 48% (12/25) with size reduction, 8% (2/25) meeting criteria for PR. SD in remainder (92%, 23/25)
- Prelim mPFS/OS 9.9/38.8mo

[Chordoma Foundation Labs @CFLabsResearch]

@DraMartinezLago @OncoAlert Encouraging ORR but note that reported PFS does not seem to match figures in the paper. Looks more like ~11 months. https://t.co/DpexeIjILI

[Chordoma Foundation Labs @CFLabsResearch]

Encouraging signal of activity from Camrelizumab (PD-1i) + Apatinib (VEGFRi) in advanced chordoma. ORR of 24% exceeds any previous systemic therapy reported. But reported PFS of 28 months does not appear consistent with patient level data shown in the paper. Follow up needed. 1/n

[Chordoma Foundation Labs @CFLabsResearch]

@Oncologynewspro @JCO_ASCO Encouraging ORR but note that reported PFS does not seem to match figures in the paper. https://t.co/DpexeIjILI

[Chordoma Foundation Labs @CFLabsResearch]

Encouraging signal of activity from Camrelizumab (PD-1i) + Apatinib (VEGFRi) in advanced chordoma. ORR of 24% exceeds any previous systemic therapy reported. But reported PFS of 28 months does not appear consistent with patient level data shown in the paper. Follow up needed. 1/n

[Chordoma Foundation Labs @CFLabsResearch]

Nonetheless there are an impressive number of responses and patients on study for >20 months which is encouraging and definitely warrants further investigation. Given chordoma’s limited vascularity it raises a question about the MOA of VEGFRi. Maybe remodeling microenvironment?

[Chordoma Foundation Labs @CFLabsResearch]

Encouraging signal of activity from Camrelizumab (PD-1i) + Apatinib (VEGFRi) in advanced chordoma. ORR of 24% exceeds any previous systemic therapy reported. But reported PFS of 28 months does not appear consistent with patient level data shown in the paper. Follow up needed. 1/n

[Chordoma Foundation Labs @CFLabsResearch]

Looks like median time on study was ~11 months. And among patients with confirmed RECIST progression, median time to progression was also ~11 months. So not clear where PFS of 28 months comes from.

[Chordoma Foundation Labs @CFLabsResearch]

@IsomorphicLabs Congrats! If helpful we can provide fast and free experimental benchmarking of predicted binders to the oncology target TBXT. And we have a prize competition for discovery of submicromolar binders: https://t.co/2meWknQ2k7. Would be interesting to see how Isomorphic performs!

[Chordoma Foundation Labs @CFLabsResearch]

@maxjaderberg Congrats Max. If helpful we can provide fast and free experimental benchmarking of predicted binders to the oncology target TBXT. And we have a prize competition for discovery of submicromolar binders: https://t.co/2meWknQ2k7. Would be interesting to see how Isomorphic performs!

[Chordoma Foundation Labs @CFLabsResearch]

@figshare Imaging mass cytometry on @BioimageA: https://t.co/HfGNSAqjW1

[Chordoma Foundation Labs @CFLabsResearch]

Important paper out from @s_vanoost, Judith Bovee &co at @LUMC_Leiden reporting two immune subtypes of chordoma with distinct transcriptional and metabolic profiles, plus contributing the first integrated spatial transcriptomics, metabolomics and lipidomics data sets to the field.

Links to data sets 👇https://t.co/ZzXzqDUYrF

[Chordoma Foundation Labs @CFLabsResearch]

GeoMX and MALDI-MSI data on @figshare: https://t.co/K5pxYriHKs

[Chordoma Foundation Labs @CFLabsResearch]

Turns out there’s a lot of interest in a fast and free experimental benchmark of AI small molecule discovery capabilities. 👀

As a result we’re announcing a few updates to the TBXT Challenge:

1. June 1, 2026 is the last date we will accept new entrants. To register and reserve testing slots, please email us at [email protected] by June 1st. (Or if you know anyone who might be interested please encourage them to get in by then)

2. To participate in the Challenge, a competitor’s first batch of compounds must be received by CF Labs by September 1, 2026.

3. Competitors with compounds found to have Kd <10 μM in their first or second batch submitted to the Challenge may step out of the Challenge and perform hit optimization under a sponsored research agreement (SRA) with CF Labs. In this scenario, the competitor has the option to fund testing of up to two rounds of 60 compounds (up to a total of 120 compounds) in the SPR assay. If a two-fold increase in potency is achieved after these two rounds, up to two additional rounds of 60 compounds may be tested. After completing testing under an SRA, a competitor may re-enter the Challenge by submitting the remainder of their 96 allotted compounds for evaluation within the Challenge.

Please reach out with any questions and good luck to those competing!

[Chordoma Foundation Labs @CFLabsResearch]

Awesome to see the @adaptyvbio protein design competition bear fruit. Great example of the power of competitions with wet lab validation to surface computational solutions to molecular design problems.

This quote from the winning team @BioMandrake stood out:

“We’re a fairly young company that’s just started out, and are setting up our wet lab as we speak. This competition was a great way for us to validate some of our hypotheses and see how they stand against actual wet lab results. The Adaptyv competition was the cleanest version of that benchmark we’d seen.”

For anyone looking for a similar opportunity to benchmark small molecule design against a difficult target, our TBXT Challenge is here for you https://t.co/uJBHTcMy3e

[Tanay Lohia @tanaylohia]

We don't even design binders!!

But we @BioMandrake just won @adaptyvbio × @gembioworkshop's RBX1 design competition - 1 Strong binder out of 322 tested, selected from 12,000+ submissions.

Couldn't make it to @iclr_conf in Rio. Here's how we did it 👇

https://t.co/Vt5lzgDRNB

[Chordoma Foundation Labs @CFLabsResearch]

@ChordomaCenter @BrownUResearch @BrownUniversity Congrats Golara! We deeply appreciate your work on chordoma and can’t wait to see where it goes from here.

[Chordoma Foundation Labs @CFLabsResearch]

@tanaylohia @BioMandrake @adaptyvbio @gembioworkshop @iclr_conf Great work! Any interest in trying your hand at small molecule design? If so we have another challenge for you :) https://t.co/vxZpwAGdZu

[Chordoma Foundation Labs @CFLabsResearch]

Congratulations to @XChemInc for an excellent AACR poster on their DEL data-driven discovery of TBXT ligands!

https://t.co/BCPFQH3xiQ

[Chordoma Foundation Labs @CFLabsResearch]

3. This immunogenic cell death is associated with secretion of immunomodulatory factors that may
enhance T cell activation and immune surveillance.

[Chordoma Foundation Labs @CFLabsResearch]

Just back from AACR where we shared results of a collaboration with @LeeZou8's lab which provide rationale for combining drugs that target DNA replication with PD-1 blockade in chordoma.

More details and link to poster "Targeting replication stress promotes immunogenic cell death in chordoma"👇

[Chordoma Foundation Labs @CFLabsResearch]

2. ATRi and Gem treatment results in accumulation of cytoplasmic dsDNA, activation of type I interferon signaling, and eATP release – consistent with an immunogenic cell death mechanism.